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Abstract 
 
 Recent advances in cancer treatment field allowed significant increase in the 
survival rate of patients. However, the patients have commonly faced long-term 
adverse effects that severly affected the quality of life, specially concerning their 
fertility. It is established that radio- and chemotherapy treatments can cause a 
reduction of the ovarian reserve, resulting in a 40-60% rate of premature ovarian failure 
(POF) in women exposed to these treatments. In order to decrease POF risks, several 
fertility preservation options were developed: reduction of the exposure to gonadotoxic 
agents, gametes or embryos cryopreservation, oocyte donation, ovarian tissue 
cryopreservation and transplant, or a pharmacological protection of the ovaries during 
chemotherapy. While the last one appears as a less invasive and promising procedure, 
the studies and clinical trials continue to show inconsistent results, raising an almost 
30-year discussion and controversy. The gonadotropin-releasing hormone (GnRH) is a 
hypothalamic hormone responsible for the releasing of gonadotropins. Due to its 
pulsatile fashion to induce FSH secretion, it was proposed that a continuous saturation 
of the receptor by synthetic GnRH analogues (GnRHa) could decrease the 
gonadotropins release and, therefore, could maintain the ovarian follicular pool at 
immature stages. Once it was suggested that initial stage follicles were less affected by 
alkylating agents, the women capacity to conceive could then be preserved. By a 
multiple approach study design, including histological, immunohistochemical, in vitro 
and in vivo assays in a mouse model, our group intended to better understand the 
potential preventive effect of GnRHa on the ovaries exposed to chemotherapy and to 
evaluate the efficiency of GnRH agonists (AGOs) and antagonists (ANTs) in this 
indication. Our results suggest, so far, that AGOs (triptorelin) and ANTs (cetrorelix) are 
not efficient to prevent the follicular depletion induced by a cyclophosphamide (Cy) 
treatment. Nevertheless, the fertility follow-up, until now, seems to show that the birth 
rate is not affected by neither Cy nor combined Cy-GnRHa treatment, suggesting that 
the mouse experimental model is not yet optimal. 
 
Keywords: fertility preservation, chemotherapy, GnRH agonists, GnRH antagonists 
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Resumo 
 
Nos últimos anos, foram feitos enormes avanços no que diz respeito aos 
tratamentos oncológicos. Estes conseguiram aumentar significativamente as taxas de 
sobrevivência e o aumento da esperança média de vida dos doentes oncológicos. No 
entanto, este incremento nem sempre foi acompanhado por uma melhoria na 
qualidade de vida, nomeadamente na preservação da fertilidade das mulheres sujeitas 
a tratamentos radio- e quimioterapeuticos. Em média, após este tipo de tratamentos, 
40-60% das mulheres são diagnosticadas com falência ovárica precoce (FOP), 
caracterizada essencialmente por uma diminuição acentuada no número de folículos 
pertencentes à reserva ovárica de mulheres ainda em idade-reprodutora, derivando 
consequentemente em amenorreia e, portanto, perda da capacidade de engravidar. 
Em suma, a FOP é essencialmente definida como uma menopausa prematura em 
mulheres com idade inferior a 40 anos. A alteração hormonal daí decorrente é 
comummente associada a um aumento no risco de aparecimento de outras 
perturbações clínicas, como a osteoporose, doenças cardivasculares e depressão. 
Desta forma, os serviços oncológicos hospitalares, em parceria com os serviços de 
ginecologia e obstetrícia, pretenderam desenvolver métodos de prevenção à FOP. A 
investigação decorrente permitiu a criação de diversas opções à preservação da 
fertilidade, tais como: a redução da exposição aos agentes gonadotóxicos, a 
criopreservação de oócitos, embriões ou mesmo de tecido ovárico para posterior 
transplantação, doação de gâmetas, ou ainda a protecção farmacológica dos ovários 
durante o tratamento quimioterapeutico. Entre estes, a protecção farmacológica surge 
como uma excelente opção para a recuperação expontânea da actividade ovárica, 
uma vez que se trata de um procedimento menos invasivo. Contudo, as conclusões 
resultantes de diversos estudos e ensaios clínicos geraram uma substancial 
controvérsia, na medida em que não surgiram ainda dados concretos e consistentes 
da efectividade dos fármacos na protecção ovárica. Apontados como o produto com 
maior potencial na prevenção da FOP, a acção de substâncias análogas (agonistas e 
antagonistas) da gonadotropin-releasing hormone (GnRH) tem sido amplamente 
estudada, tanto em modelos animais como em ensaios clínicos em humanos. A GnRH 
é uma hormona sintetizada no hipotálamo, cuja função é o controlo da secreção das 
gonadotropinas FSH e LH na hipófise anterior. A produção de FSH e LH está 
dependente de um estímulo de carácter pulsátil da GnRH. Visto isto, a exposição 
permanente dos receptores hipofisários aos análogos da GnRH (GnRHa) origina uma 
inibição na secreção das gonadotropinas, que desta forma não acederão ao ovário, 
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impedindo o normal desenvolvimento folicular. Como anteriormente referido existem 
duas classes de GnRHa: agonistas (AGOs) e antagonistas (ANTs). Os AGOs têm 
relativamente poucas alterações em comparação com a hormona natural. São 
igualmente decapéptidos, cujas modificações ocorrem essencialmente ao nível do 
aminoácido na 6ª posição (glicina), que aumenta o tempo de meia-vida da hormona, 
protegendo-a da degradação por peptidases; na 10ª posição (glicina 
carboxiloterminal), que  melhora a afinidade do GnRHa ao receptor (GNRHR). 
Relativamente aos ANTs, estes podem conter múltiplas alterações, ocorrendo 
sobretudo nas três primeiras posições – região de ligação ao GnRHR. Os GnRHa 
foram desenvolvidos com vista à alteração da produção de gonadotropinas. Os AGOs 
induzem primeiramente uma forte secreção, no entanto a contínua administração 
provoca uma saturação do complexo AGO-GnRHR, originando uma queda acentuada 
na concentração de FSH e LH circulantes (produzidas e excretadas apenas na 
existência de uma actividade pulsátil da GnRH). Por outro lado, os ANT actuam por via 
duma competição com a hormona natural pelo GnRHR, bloqueando estes e 
suprimindo assim a normal actividade da GnRH na hipófise. Alguns autores propõem 
que esta actividade inibitória, de ambos os GnRHa, é capaz de proteger a reserva 
ovárica dos efeitos da quimioterapia, uma vez que esta incide sobretudo nos folículos 
que se encontram em desenvolvimento. Ou seja, a criação de condições 
hipopituitárias, poderá impedir a secreção de FSH – hormona essencial ao 
crescimento e ao recrutamento folicular –, e assim impossibilitar a acção de agentes 
quimioterapeuticos, cuja intervenção incide sobretudo nas células com actividade 
proliferativa. Concretamente, a nível das células da granulosa – células do folículo 
ovárico de maior actividade mitótica. 
As primeiras demonstrações de um possível efeito protector dos GnRHa num 
ovário exposto a quimioterapia ocorreram nos anos 80, em experiências que 
utilizavam o rato como modelo. Estas apresentaram resultados animadores, uma vez 
que o AGO utilizado conseguia diminuir a depleção de folículos ováricos de ratos 
tratados simultaneamente com ciclofosfamida (agente quimioterapeutico). 
Posteriormente, um estudo com macacos rhesus demonstrou que a ciclofosfamida 
destruía 65% dos folículos primordiais, enquanto que um co-tratamento com AGO 
reduzia esta população folicular em apenas 29%. No entanto, outros estudos 
demonstraram diferenças não significativas entre as várias condições analisadas, 
levantando então dúvidas relativamente ao sucesso dos AGOs na preservação da 
fertilidade. Comparativamente, o uso de ANTs em modelos animais expostos a 
tratamentos quimioterapeuticos, demonstrou alguns casos promissores, mas não na 
totalidade. Um estudo recente, apresentou uma menor depleção da reserva folicular 
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em ratinhos co-tratados com ciclofosfamida e cetrorelix (ANT), quando comparada 
com os ratinhos expostos apenas à ciclofosfamida. Contudo, outro estudo afirmou que, 
embora a diferença nas contagens de folículos efectivamente ocorresse, a diminuição 
não se repercutia posteriormente numa diferença significativa no número de crias por 
ninhada, nas várias condições analisadas. No que respeita à investigação em 
humanos, diversos estudos foram já realizados, porém com a controvérsia da acção 
dos GnRHa na protecção do ovário a manter-se. As conclusões de inúmeros estudos 
foram postas em causa, devido à metodologia utilizada e ao carácter incompleto de 
alguns ou pelo reduzido número e em enviesamento da amostra de outros. No 
entanto, ensaios clínicos mais recentes, cuja pretensão se centrou na avaliação mais 
rigorosa do efeito dos GnRHa, continuam a fornecer resultados preliminares e 
conclusões inconsistentes e díspares uns dos outros. Mantendo-se assim a discussão 
sobre o verdadeiro efeito dos GnRHa nos ovários de mulheres submetidas a 
quimioterapia, e desconhecendo-se igualmente os mecanismos fisiológicos 
subjacentes à acção destes. 
Visto isto, o presente estudo pretendeu melhor elucidar o potencial efeito 
protector dos GnRHa nos ovários durante a quimioterapia, assim como comparar a 
eficácia de AGOs e ANTs no desempenho desta função preventiva. Recorrendo ao 
ratinho como modelo, este estudo contem diferentes abordagens, de forma a tentar 
responder com complementaridade a diversas questões, avaliando assim de forma 
mais generalizada o papel dos GnRHa: a reserva ovárica foi avaliada através de 
contagem folicular por fase de desenvolvimento, recorrendo a técnicas histológicas 
(coloração hematoxilina e eosina); as taxas de proliferação celular e apoptose foram 
avaliadas por imunohistoquímica (ki-67 e caspase-3, respectivamente); o 
desenvolvimento folicular foi analisado através de culturas in vitro (12 dias em meio de 
crescimento + 1 dia em meio de maturação, e consequente desnudagem e avaliação 
do estado de maturação do oócito); a fertilidade foi estudada a partir do 
acompanhamento das ninhadas produzidas; a competência do oócitos  foi verificada 
pela técnica de fertilização in vitro (embora os resultados não sejam apresentados 
neste estudo). Seis condições de tratamento foram definidas: controlo – aos ratinhos 
fêmea foi diariamente administrada uma injecção subcutânea (sc) de uma solução 
salina (NaCl) e uma única injecção intraperitoneal (ip) foi aplicada, igualmente, com 
NaCl; controlo-quimioterapia – sc diária NaCl e uma única ip de ciclofosfamida (Cy); 
controlo-ANT – sc diária cetrorelix e uma única ip NaCl; ANT-quimioterapia – sc diária 
cetrorelix e uma única ip Cy; controlo-AGO – sc diária triptorelin e uma única ip NaCl; 
AGO-quimioterapia – sc diária triptorelin e uma única ip Cy. Os ratinhos fêmea 
receberam tratamento base durante 21 dias e a ip foi administrada no dia 13. No dia 
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do sacrifício foi recolhido sangue, com recurso a uma punção intracardíaca; a cada 
dois dias das culturas foliculares in vitro o meio de cultura era colhido, renovado e 
armazenado. Todas as colheitas armazenadas serviram posteriormente para que 
análises hormonais fossem efectuadas. A comparação entre o efeito produzido pelo 
AGO e ANT na reserva folicular, demonstrou que o grupo controlo foi aquele cujo 
número de folículos em estados iniciais – primordiais e primários – era mais elevado 
(441 ± 153). Embora as diferenças notadas não tenham atingido valores 
estatisticamente significativos (p=0,358), o grupos controlo-ANT e controlo-AGO 
apresentaram um decréscimo, respectivamente, de 17% e 23%, em comparação com 
o controlo. Relativamente aos grupos tratados com Cy, todos demonstraram 
novamente valores proporcionais inferiores (comparativamente ao controlo): Cy – 
menos 32%; ANT+Cy – menos 39%; AGO+Cy – menos 44% (o único a atingir valores 
significativos, p=0,022). Os folículos em crescimento – secundários, early antrais e 
antrais – apresentaram contagens sem diferenças significativas entre todas as 
condições. A proporção relativa dos vários estadios de desenvolvimento folicular 
demonstraram valores muito próximos, entre todas as condições. A percentagem de 
folículos em estados iniciais variou entre 66-78% e a de folículos em crescimento 22-
34%. Testes imunohistoquímicos preliminares à proteína ki-67 parecem marcar 
preferencialmente as células da granulosa de folículos em crescimento. No que 
concerne as culturas foliculares in vitro, a taxa de sobrevivência foi semelhante em 
todas as condições, assim como na taxa de maturação ovocitária. Todas as condições 
apresentaram uma taxa de oócitos em meiose II entre 51-67%. A produção de 
progesterona (24h) também não apresentou diferenças significativas entre condições, 
tendo o grupo controlo revelado uma produção de 2,89 ng/mL. O acompanhamento 
dos nascimentos ocorridos não demonstrou, até ao momento, nenhuma diferença 
entre os vários grupos analisados. 
Os resultados até agora obtidos parecem sugerir uma ausência de efeito 
protector na reserva folicular, aquando o uso de GnRHa em ovários expostos a 
ciclofosfamida. No entanto, o projecto encontra-se ainda a decorrer, pelo que mais e 
melhores informações deverão elucidar de forma mais clara o verdadeiro papel dos 
GnRHa no ovário submetido a tratamento quimioterapeutico. 
 
Palavras-chave: preservação da fertilidade, quimioterapia, agonistas da GnRH, 
antagonistas da GnRH 
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Introduction 
 
Over the last years, the progresses in the cancer treatment field allow to 
remarkably improve survival rates among patients. A recent report from the Office for 
National Statistics of the United Kingdom (UK) says that, presently, near 10% of 
women face or will face breast cancer – the most common malignancy in adult women; 
however, the 5-year survival rate for women treated for breast cancer in the UK is now 
above 80% (ONS, 2010). The development in radio- and chemotherapy treatments 
created, nonetheless, a clinical concern related to the long-term adverse effects of 
cancer treatments. Chemotherapy-treated women are frequently diagnosed with early 
menopause, or with an increase in infertility rate even in those who recover their 
ovarian function after chemotherapy. These adverse events dramatically affect their 
quality of life (Letourneau et al., 2012). The premature ovarian failure (POF) has also 
been related to an increase risk of osteoporosis (Bruning et al., 1990), cardiovascular 
diseases (Jeanes et al., 2007) and psychosocial problems, such as depression (Carter 
et al., 2005). This early menopause is specifically characterised by a premature 
depletion of functional ovarian follicles leading to the arrest of the menstrual cycle – 
amenorrhea – in women of reproductive age (Goswami et al., 2005). It is usually 
established that 40-60% of women diagnosed with invasive cancer will face POF 
(Meirow, 2000). Therefore, fertility preservation in reproductive-aged women became a 
major concern in oncologic units.  
 
Several options for the preservation of women fertility have been developed, 
such as: reduction of the gonadotoxic treatments, cryopreservation of gametes or 
embryos, oocyte donation, ovarian tissue cryopreservation and transplant, or even a 
pharmacological protection of the ovaries during chemotherapy (Figure 1). For medical 
or personal (or also legal) reasons, the established fertility preservation methods are 
not always available or indicated to all patients.  
 
Regarding these issues, pharmacological protection could represent an 
interesting option to increase the chances of spontaneous ovarian function recovery 
after chemotherapy, avoiding more invasive procedures. The administration of the 
Gonadotropin-releasing hormone (GnRH) agonist has been proposed as potential 
“ferto-protective” therapy during chemotherapy. 
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Figure 1: Different options available for cancer patients on order to preserve their 
fertility (Demeestere et al., 2007). 
 
The identity and structure of the GnRH were first described in the work of 
Schally and his colleagues (Schally et al., 1971). Among the key events, after this 
discovery, authors described the pulsatile fashion of GnRH release in the circulation 
(Knobil, 1974) and demonstrated that these pulses are crucial to maintain the synthesis 
and secretion of gonadotropins – follicle-stimulating hormone (FSH) and luteinizing 
hormone (LH) – and so the reproductive function (Knobil, 1980). 
 
The core of GnRH-secreting neurons is located in the medial basal 
hypothalamus (Figure 2). Once released, the GnRH penetrates directly on the 
hypophyseal portal system vessels and reaches the anterior pituitary. Then, the GnRH 
binds to a receptor (GnRHR) expressed in gonadotropic hypophyseal cells that 
subsequently secrete FSH and LH (Naor, 2009). The gonadotropin secretion stimulus 
is dependent on this GnRH pulsatile release, once that the continuous exposure of the 
receptors to GnRH downregulates the LH and FSH secretion (Bédécarrats et al., 
2003). 
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Figure 2: Hypothalamic-hypophyseal-gonadal axis (Cakmak & Seli 2012). 
 
Two classes of GnRH analogues where synthetized as a therapeutic option for 
different diseases: GnRH agonists (AGOs) and GnRH antagonists (ANTs). The human 
GnRH is a decapeptide with the following amino acid sequence: Glutamic acid – 
Histidine – Tryptophan – Serine – Tyrosine – Glycine – Leucine – Arginine – Proline – 
Glycine (Figure 3). 
Regarding GnRH agonists, they have relatively few modifications compared to 
the native GnRH. Modifications concern the glycine at position 6 and the 
carboxyterminal glycine at position 10. The modification at position 6 increases the 
half-life of the molecule by protecting the hormone from degradation, since this position 
is the target of peptidases. The modification at position 10 increases the receptor 
affinity by 100-200 times (Shapiro, 2003).  
On the other hand, GnRH antagonists have multiple substitutions. Among them, 
the majority are on the amino acids at the positions 1, 2 and 3, the receptor-binding 
region (Shapiro, 2003). 
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 Figure 3: GnRH amino acid sequence. 
 
These synthetic drugs (the GnRHa) were designed to modify the release of 
gonadotropins. As previously mentioned, GnRH agonists have similar structure 
compared to native GnRH and a higher affinity to the GnRHRs. Firstly, they induce 
gonadotropins release (flare-up effect), but after a continuous administration they result 
in a dramatic drop of the circulating concentrations of FSH and LH through a 
desensitization mechanism. GnRH agonists have a greater affinity for the GnRHR than 
native GnRH, a greater resistance to enzymatic breakdown and a prolonged half-life 
compared to native GnRH (in humans, native GnRH has a half-life of 2–4 min 
compared to 3h for GnRH agonist, leuprolide) (Chillik et al., 2001). The prolonged 
saturation of the AGO–receptor complex leads to a profound inhibition of the 
gonadotropins secretion (Ortmann et al., 2002). Although they have the same function, 
GnRH antagonists act through different mechanisms causing immediate gonadotropin 
release suppression by competitively blocking GnRHRs in the pituitary (Horvath et al., 
2002). 
 
Some authors suggested that GnRHa may protect the ovary during 
chemotherapy thanks to their inhibitory effect on gonadotropins secretion and therefore 
on the ovarian function.  The presence of FSH is indeed essential for follicular growth 
(Gougeon, 1996). During hypopituitary conditions, the follicular growth is partially 
abolished. Low FSH levels induced by GnRHa could also inhibit the process of 
recruitment from the pool of small follicles to the pool of larger follicles. This is 
suggested by a study analysing the Thymidine3 incorporation into ovarian DNA, which 
demonstrated that GnRHa could suppress granulosa cells mitotic activity (Ataya et al., 
1988). Dividing cells are known to be more sensitive to the cytotoxic effects of 
chemotherapeutic agents than the cells at resting stage. Furthermore, high levels of 
gonadotropins are associated with an increase of the normal follicular atresia process. 
This is confirmed by the following observation: in postnatal normal rodents, plasma 
FSH is elevated up to 18 days of life. During this period, the remaining follicular stock 
decreases by half (Gougeon, 1996). Inversely, low levels of gonadotropins 
encountered in hypophysectomy decrease the normal process of progressive loss of 
oocytes. Elevated gonadotropin serum levels frequently observed during chemotherapy 
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could produce an increase of the follicular atresia process. By inhibiting the 
gonadotropin secretion, GnRHa could reduce the rate of atresia and protect the ovary 
during chemotherapy. 
 
The effectiveness of the GnRH agonist treatment was first reported in rats and 
monkeys in the 1980s. Studies on rats treated with Cyclophosphamide (Cy) combined 
with AGO showed a decrease in the chemotherapy-induced follicular depletion by 
maintaining the follicular pool at the resting stage (Ataya et al., 1988; Ataya et al., 
1989). Experiments on monkeys demonstrated that 65% of the primordial follicular pool 
is destroyed after Cy treatment compared to 29% after Cy+AGO treatment. The 
primordial follicles declining rate per day is significantly reduced in the combined 
treatment group compared to the Cy treatment group (0.06% vs. 0.12%) (Ataya et al., 
1995). Tan and his fellows obtained a greater number of primordial and primary follicles 
when a high-dose of agonist was applied simultaneously with a busulfan treatment 
(Tan et al., 2010). In contrast, Montz et al., reported that Lupron (an AGO) was able to 
preserve fertility in rats exposed to the gonadotoxic effect of Cy, but failed to protect 
fecundity (Montz et al., 1991). Concerning the co-treatment of GnRH antagonists along 
with chemotherapy, Meirow’s group showed in 2004, a promising study where the co-
administration of cetrorelix contributed to a minor ovarian damage and greater 
primordial follicles count when compared with the Cy-only group, on a mice model 
(Meirow et al., 2004). In the study of Lemos et al., they found a histological significant 
difference in the follicular count of the group of rats treated only with ANT (compared 
with the control), however the number of pups that were born were not statistically 
different (Lemos et al., 2010). The efficiency of these treatments was however 
seriously debated since many years. Other authors support that the treatment cannot 
efficiently inhibit the initial activation and growth of the primordial follicles as this phase 
is gonodotrophins independent (Oktay et al., 2007). Furthermore, others study did not 
show any benefit of the administration of GnRha concomitantly to the chemotherapy on 
the fertility (Montz et al., 1991) and even showed a detrimental effect (Maltaris et al., 
2007). 
 
In humans, the efficiency of GnRHa in preventing premature ovarian failure 
remains also controversial. Some non-randomized studies suggested a reduction of 
premature ovarian failure rate when AGO was administered concomitantly to the 
chemotherapy (Blumenfeld et al., 2008; Castelo-Branco et al., 2007; Dann et al., 2005; 
Huser et al., 2008; Pereyra Pacheco et al., 2001). However, the methodology of these 
studies was criticized, thus calling the results into question (Beck-Fruchter et al., 2008). 
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After the observation, by some, of a beneficial effect of GnRH agonists on future 
ovarian function, new, larger and prospective randomized studies have been initiated. 
In 1987, Waxman and colleagues demonstrated that buserelin (AGO) was ineffective in 
conserving fertility in a group of Hodgkin’s lymphoma patients (Waxman et al., 
1987).The Gruppo Italiano Mammella indicated a reduction of 17% in the occurrence of 
POF in the cohort group treated simultaneously with chemotherapy and triptorelin (Del 
Mastro et al., 2011). On the other side, also resorting to breast cancer patients (like the 
previous mentioned study), Munster et al., reported comparable amenorrhea rates in 
the triptorelin/chemotherapy-treated and control groups (Munster et al., 2012). In 2010, 
the German Hodgkin Study Group presented an ovarian follicle preservation rate of 0% 
in all studied groups, in a clinical trial where oral contraceptives and goserelin were 
independently tested for the ovary protection during an escalated combination 
chemotherapy regimen in advanced-stage Hodgkin lymphoma patients (Behringer et 
al., 2010). Likewise, Demeestere et al., are currently at the end of the first year of 
follow-up of a multicentre, randomised, prospective trial including Hodgkin’s and non-
Hodgkin’s lymphoma patients, and the results show approximately 20% of POF either 
in the triptorelin co-treated or in the control arm (Demeestere et al., 2012)  
Nevertheless, despite some of these clinical trials suggest an effect of GnRH 
agonist to protect the ovarian reserve of patients who spontaneously recover their 
ovarian function, the physiological mechanisms of ovarian protection is still poorly 
described and controversial. 
 
Therefore, our project intended to contribute for a better understanding of the 
protective effect GnRHa on the ovary during chemotherapy and to compare the 
efficiency of GnRH agonist and GnRH antagonist using mice model. The study had 
several different approaches, in order to evaluate: the ovarian reserve (histological 
follicular count), the follicular proliferation and the apoptotic rates 
(immunohistochemistry), the follicular developmental potential (in vitro follicular culture 
system), the fertility (follow-up of the litter size) and oocyte competence (IVF).  
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Material and Methods 
 
Animals 
 
All experiments were performed using F1 females hybrid mice (C57blxCBAca, 
Harlan, The Netherlands) aged 6-8 weeks at the beginning of the treatments. The 
animals had free access to food and water, and they were kept under the specific 
conditions approved by the institution’s ethics committee.  
 
Drug treatments 
 
The experiments were designed to compare 2 different GnRH analogues 
(GnRHa): cetrorelix acetate - GnRH antagonist (ANT) (Cetrotide®, Merck Serono, 
Switzerland); triptorelin acetate - GnRH agonist (AGO) (Gonapeptyl®, Ferring 
Pharmaceuticals, Switzerland). For the chemotherapy, an alkylating agent was used: 
Cyclophosphamide monohydrate (Cy) (Sigma-Aldrich, USA) 
Each experiment was conducted using two female mice per condition, who 
received the same treatment: a daily 100 µl subcutaneous injection of the GnRHa (0,5 
mg/kg) or vehicle only (NaCl, saline solution) during twenty-one days and a single 100 
µl intraperitoneal injection of Cy (75 mg/kg) or vehicle on day 14. This dose of 
chemotherapy is supposed to destroy half of the ovarian reserve (Meirow, 1999). The 
conditions included the following groups:  
 Control (vehicle only)  
 Chemotherapy-control (daily vehicle and once Cy)  
 Antagonist-control (daily ANT and once vehicle)  
 Antagonist-chemotherapy (daily ANT and once Cy)  
 Agonist-control (daily AGO and once vehicle) 
 Agonist-chemotherapy (daily AGO and once Cy) 
The injected doses were chosen based on previous studies that showed significant 
ovarian dose-response effects (D Meirow 1999; Dror Meirow et al.,. 2004).  
  
Peripheral blood intra-cardiac puncture 
 
 On the 21st day of the treatments, all the females (with the exception of those 
from the follow-up assay) were anesthetised with an intra-peritoneal injection of saline 
solution containing 10% xylazine 2% (Rompun®, Bayer, Germany) and 20% ketamine 
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HCl (Ketamine 1000®, Ceva, Belgium), and an intra-cardiac puncture (IC) was made 
with a 26-gauge needle to collect peripheral blood. A mean of 600 µl of blood per 
mouse was collected to Eppendorf® tubes, and then centrifuged at 13 x 105 rpm for 10 
min, so that the blood serum could be saved and used in further hormonal assay. The 
mice were sacrificed immediately after the IC by cervical dislocation.  
 
Follicular count 
 
Subsequently to the IC and cervical dislocation, the mice were ovariectomised. 
For each mouse, one ovary was fixed in 4% paraformaldehyde overnight, embedded in 
paraffin and serially sectioned in the microtome into 5 m slices. Sections were stained 
resorting to Haematoxylin–Eosin coloration and the number of follicles was counted 
and properly classified in every 5th section. Follicles were classified according to the 
granulosa cells layers and counted only when the oocyte nucleus was visible in the 
section. The follicular development and classification was divided into five stages 
(Figure 1): primordial – with a single flat granulosa cells layer; primary – with single 
layer of cuboidal granulosa cells; secondary – more than 1,5 layers of granulosa cells; 
early antral – multiple granulosa cells layers and presence of cavity(ies), synonym of 
the formation of an antrum; antral – antrum fully formed, with the oocyte located 
already on the periphery of the follicle surrounded by the cumulus cells (cumulus 
oophorus). The counting was made unaware of which condition was being analysed. 
The final results do not present any kind of extrapolation or correction factor, which 
means that the values showed on this study can’t be seen as a representation of the 
whole ovary. 
 
 
 
 
 
 
Figure 4: Classification of the different follicles developmental stages in adult mice 
ovaries 
 
Preantral follicles culture 
 
The other ovary was dissected using a 26-gauge needle in order to isolate 
Primordial  Primary Preantral Early antral      Antral
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preantral follicles. Only intact preantral follicles, with diameter between 100-130 m 
and characterized by at least two complete granulosa cell layer and a visible centrally 
located oocyte, were selected for culture. The culture medium is composed of MEM 
Glutamax supplemented with 5% FBS, 1% ITS (Insulin 5 µg/ml, Transferrin 5 µg/ml, 
Selenium 5 ng/ml), 1% r-LH (80 mIU/ml), 0,1% r-FSH (100 mIU/ml). Each selected 
follicle was rinsed, individually transferred in a microdrop of 10 l of culture medium 
under mineral oil and cultured at 37°C in a humidified atmosphere of 5 % C02 in air. 
After two days of culture, 10 l of fresh medium were added in each drop. Every 2 days 
until day 12 of culture, 10 l of medium of each drop was collected and replaced by 
fresh medium. The collected culture media from the drops containing surviving follicles 
was pooled and stored at – 20°C until further hormonal assays. After 12 days of 
culture, oocyte maturation was induced by refreshing the medium with maturation 
medium. The maturation medium consisted of culture medium supplemented with 1,5 
IU/ml r-hCG and 5 ng/ml EGF. Sixteen to eighteen hours post r-hCG/EGF, oocyte-
cumulus-complexes (OCC) were collected and mechanically denuded to evaluate the 
oocyte nuclear maturation stage. Three stages were defined according to the 
maturation and temporal development of the oocyte (Figure 2): germinal vesicle (GV) – 
where a circular vesicle (oocyte nucleus) is visible inside the oocyte cytoplasm (in 
prophase I of meiosis); germinal vesicle breakdown or first meiosis (GVBD/MI) – stage 
where the vesicle is no more discernible; second meiosis (MII) – the vesicle is not 
observable and the first polar body is already present. 
 
 
 
 
 
 
Figure 5: Schematic illustration of the major steps of the oocyte maturation (modified 
from Swain and Pool, 2008) 
 
Immunohistochemistry: 
 
In order to evaluate the proportion of granulosa cells in proliferation, an 
immunohistochemistry protocol was optimised for the Ki-67 staining, as it is an 
extensively used cell proliferation marker. After deparaffinisation and rehydration, 
slides were rinsed in PBS and then transferred into a citrate buffer, placed in the 
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microwave for 5 min, cooled down for 5 min and rinsed again in PBS. An endogenous 
peroxidase inhibition has followed, using 3% H2O2/methanol solution for 30 min and 
then washing in tap and distilled water. Normal goat serum (5% NGS) in PBS was 
added for 1 hour at room temperature. After rinsing with PBS, all endogenous biotin, 
biotin receptors, and avidin binding sites of the sections were blocked, by covering the 
sections with avidin/biotin blocking kit drops, for 15 min (SP-2001, Vector Laboratories, 
US) and again washed in PBS. The sections were then incubated at 4ºC overnight with 
rabbit monoclonal antibody against Ki-67 (VP-RM04, Vector Laboratories, US), diluted 
1:200/1:400 in 5% NGS in PBS. Following the primary antibody incubation, the slides 
were washed in PBS and the secondary antibody (Biotinylated Goat Anti-Rabbit IgG, 
dilution 1:300, BA-1000, Vector Laboratories, US) was added for a period of 1 hour at 
room temperature. After PBS rinsing, an Avidin/Biotinylated Enzyme Complex (PK-
6100, VECTASTAIN Elite ABC kit, Vector Laboratories, USA) was used for an 
incubation time of 30 min, followed by a peroxidase activity development produced by a 
3,3’-diaminobenzidine solution (SK-4100, DAB Peroxidase Substrate Kit, Vector 
Laboratories, USA) for 5 min. The slides were finally washed in tap and distilled water, 
counter-stained with toluidine blue, dehydrated and mounted. The negative control was 
processed identically, with the primary antibody being replaced by an IgG rabbit 
(dilution 1:5000). 
 
Hormonal analyses 
 
Serum levels of progesterone were determined using an automatic electro-
chemiluminiscent technique (Model E170, Roche, Mannheim, Germany), diluted 1:3 in 
Progesterone standard diluent (Diagnostic Products Corporation, USA). The sensitivity 
and inter-assay coefficient of variations were, respectively, 0.25 ng/ml and <5%. 
 
Statistics 
 
Statistical analyses were performed using SPSS or Vassar Stats website. The 
follicular count was compared using ANOVA tests. Follicular maturation was compared 
using Fisher’s exact test. Values of p<0.05 indicated statistical significance. 
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Experimental design 
 
The experimental design was partially reproduced and adapted from a previous 
study (Meirow, 2004). The two first experiments were performed to evaluate the two 
chosen GnRHa and Cy doses, previously described in the literature. 
 Three experiments were performed to evaluate the histological aspect and the 
follicular count, to execute immunohistological tests and follicular in vitro cultures (in 
total: six mice/condition). A fourth assay was made only for follicular culture, using both 
ovaries of all mice, in order to achieve a greater number of follicles per condition 
(external controls were used this time, to histologically testify that the treatments were 
well performed) (two mice/condition);  
Three additional assays were performed to evaluate the long-term fertility effect 
(in total: six mice/condition), with individual mating of the treated females with a F1 
hybrid male. As this study was designed to evaluate the efficiency of GnRHa to prevent 
future fertility decline induced by chemotherapy, the GnRHa-control groups were not 
included.  
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Results 
 
None of the mice died during the treatments, and only a female from the follow-
up assay died after the birth of its 3rd litter. 
 
Preliminary tests 
 
 The two first series were performed to evaluate if the GnRHa and Cy 
concentrations used had a similar effect as previously described when compared with 
the controls. Four treatment conditions were included in each treatment group (ANT 
and AGO). In each of the assays, two female mice were used per condition, and both 
of its ovaries were counted separately (total n=16; n/condition=2; n 
ovaries/condition=4). The follicular count was regrouped into two classes: initial stage 
(primordial + primary) and growing stage (secondary + early antral + antral) (Figure 6). 
 
Figure 6: Total number of follicle count according to the treatment  
 
In the ANT assay, the mean (±SD) number of follicles of the control group in the 
initial stage was 424 ± 65 and in the growing stage 122 ± 14. When compared with the 
control, the chemotherapy-control group presented a decrease of 22% in the initial 
stage and 9% in the growing stage ones. Concerning the ANT-control group and the 
co-treated ANT+Cy group, they showed, respectively, a decrease of 15% and 10% of 
the initial stage (p=0.177), and 8% and 2% of the growing stage, respectively (p=0.81) 
(Figure 7). Nevertheless, when comparing the groups treated with Cy alone vs 
ANT+Cy, an increase of 15% and 8% of the follicular population at initial and growing 
stage, respectively, was observed. 
    initial     growing 
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Figure 7: Depletion rate of the initial stage (A) and growing stage (B) ovarian follicular 
population after the first preliminary ANT treatment assay, comparing with the control. 
 
In the AGO assay, the control group revealed in the initial stage 452 ± 117 
follicles, in the final stage 144 ± 16. When compared with the control, the 
chemotherapy-control group presented a decrease of 37% in the initial stage and 34% 
in the growing stage. Concerning the AGO-control and the co-treated AGO+Cy groups, 
they showed, respectively, a decrease of 39% and 23% of the initial population 
(p=0.078) and of 19% and 11% of the growing population (p=0.1) respectively, when 
compared with the control group (Figure 8). When the groups treated with Cy alone vs 
AGO+Cy were compared, an increase of 23% and 35% of the follicular population at 
initial and growing stage respectively was observed. 
Despite the absence of significance due to the limited number of ovaries and 
the inter-variability, we considered the Cy doses as sufficiently efficient to continue the 
experiment.   
 
 
 
 
 
 
 
 
 
Figure 8: Depletion rate of the initial stage (A) and growing stage (B) ovarian follicular 
population after the first preliminary AGO treatment assay, comparing with the control. 
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Comparison of GnRH agonist and antagonist effect on the follicular reserve 
 
These results encompass the analysis of three series, each one including two 
mice per condition with the follicular count of one ovary/mouse, the other ovary was 
used for follicular culture (n total=36; n/condition=6).   
 
 
Figure 9: Histological mouse ovary sections with haematoxylin and eosin staining. 
Entire ovary (a); primordial follicle (b); primary follicle (c); secondary follicle (d); early 
antral follicle (e); antral follicle (f). Scale bar: 50 µm (section a – scale bar: 100 µm). 
 
 
Figure 10: Mean follicular count for each stage according to the treatment conditions. 
Five-stage classification (A) and re-grouped two-stage classification (B). 
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The control group had the highest mean of follicles at the initial stages: 441 ± 
153; but no significant difference was observed with the mice treated with GnRHa 
alone: ANT – 367 ± 74; AGO – 340 ± 89 (p=0.358) (see Figure 10). The follicular 
depletion rate compared to control was 17% and 8% for the ANT group, and of 23% 
and 1% in the AGO group for the initial and growing population respectively (Figure 
11). Regarding the Cy-treated mice, an important reduction in the follicular reserve is 
exhibited in all three groups, when compared with the control group: Cy – 300 ± 82 (-
32%), ANT+Cy – 270 ± 73 (-39%), AGO+Cy – 247 ± 51 (-44%), reaching statistical 
significance for the last one (p=0.022). No significant difference was observed between 
conditions regarding the counting of follicles in the growing stage population (Figure 
11B).  
 
 
Figure 11: Depletion rate of the initial stage (A) and growing stage (B) ovarian follicular 
population after GnRHa treatments, comparing with the control. 
 
 
The proportion of each follicular stage is conserved through all treatment 
conditions. The relative percentages range between 66-78% for the initial stage follicles 
and 22-34% for the growing stage ones (Figure 12).  
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Figure 12: Mean proportion of follicles for each stage according to the treatment 
conditions. 
 
Immunohistochemistry 
 
Preliminary tests showed that the Ki-67 staining seem to preferentially mark the 
granulosa cells in proliferation, from growing follicles, such as secondary (Figure 13) 
and early antral follicles. Ongoing experiments to evaluate a possible difference 
between treatment groups are being performed. 
 
 
Figure 13: Ki-67 immunostaining on a control mouse ovary. Red arrows indicate 
secondary follicles with stained granulosa cells. Yellow arrows indicate non-stained 
primary follicles (a). Mouse intestine with epithelial cells stained (b). Scale bars: 100 
µm. 
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Follicular in vitro culture 
 
Following the mice sacrifice and ovariectomy, one ovary from each mouse was 
carefully dissected (exception made in the fourth assay, where both ovaries from each 
mouse were used), in order to collect the preantral follicles, which were cultured 
separately in individual drops of medium. A total of 585 follicles from the different 
treatment conditions were cultured (56 ovaries from 48 mice; i.e., 8 per condition). In 
vitro follicular growth is illustrated in the Figure 14. 
 
 
 
Figure 14: Follicular in vitro maturation. Follicles in culture day 2 (a), day 4 (b), day 10 
(c), day 12 (d) and day 13 (e). This last presents the oocyte already outside the 
granulosa cell layers, after finished the maturation process, but still surrounded by 
cumulus cells. Scale bar: 50 µm. 
 
The follicles were observed every two days to report the survival rate. A 
degenerated follicle was characterised, preferably by a complete oocyte expulsion 
followed by the detachment or demise of the granulosa cell layers, by a permanent 
wrinkled surface, or by the non-attachment to the bottom of the culture dish after a few 
days. No difference was observed between the follicular survival rates in the different 
treatment conditions (see Figure 15A).   
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43 18 16 77 
 
 
Figure 15: Follicles survival rate when cultured in vitro, depending on the treatment (A). 
Proportion of oocyte nuclear stages on Meiosis II (MII), Meiosis I (MI) or germinal 
vesicle (GV), in the different conditions (B). 
 
No significant difference was observed in the oocytes maturation rate at day 13. 
Once the control group presented 63% of oocytes in the MII stage (see Figure 15B) 
and all the other ones ranging between 51-67%, one can conclude that the previous 
treatment condition have no impact on the capacity of the survival follicles to mature in 
vitro. 
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Figure 16: Isolated oocytes at three maturation stages: germinal vesicle (GV), Meiosis I 
(MI) and Meiosis II (MII). Scale bar: 50 µm. 
 
Hormonal analysis 
 
With the collected serum from the different condition culture drops of day 13, 
the levels of progesterone secreted to medium were measured. The control group had 
a 24 hour-average production of 2,89 ng/mL of progesterone (Figure 17). The former 
groups did not show statistically significant differences, although the GnRHa-alone 
treatments appear with an interesting smaller progesterone production in response to 
hCG. 
 
 
Figure 17: Progesterone 24 hour-average production in control and treated conditions 
(from day 12 to day 13). 
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Fertility follow-up 
 
Three injection series were performed to evaluate the long-term mouse pups 
rate after treatments. Hence, after the treatments have ended, all the females were 
individually mated. This analysis included the mean litter size of 36 mice couples (6 
couples per condition). As the series were not done all at once, the results from the 
fourth litter (including) and further on, presented in Figure 18 belong only to two 
couples (the first two treated females for each condition). 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Variation of the average number of mouse pups per litter in several analysed 
conditions.  
 
The average number of new-borns per litter is very close between all conditions, 
and is also increasing (until the conclusion of this work). No significant differences are 
noted, therefore suggesting that the treatments have no effect on the mice fertility, at 
least in short/medium-term. Moreover, the average number of days between births was 
fairly close, with an overall mean of new mouse pups born every 23 days. 
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Discussion 
 
 Although the accomplishment of new cancer treatments could significantly 
improve the lifespan of patients, the corresponding improvement in the quality of life 
cannot always be achieved. Specifically, major concerns are addressed regarding the 
female population, which rightfully intends the safeguarding of their fertility. 
Numerous studies have confirmed the irreparable ovarian toxicity caused by 
alkylating chemotherapy regimens (Mattison e al., 1981; Meirow, 1999; Oktem et al., 
2007). These treatments have, almost constantly, severe side effects, leading to the 
development of premature ovarian failure (POF) during reproductive-age, and 
consequently to the impossibility to conceive (Blumenfeld et al., 2008; Sonmezer et al., 
2004). Therefore, different options have been proposed to preserve the fertility of these 
young patients, including pharmacological protection. 
The present study aims to evaluate the validity of the mice model to further 
compare the mechanisms of action and the efficiency of the GnRh analogues to 
prevent chemotherapy-induced ovarian damage. It must be highlighted that this study 
and this report are the beginning of an ongoing project, and therefore the small amount 
of individuals, must be taken into consideration in the interpretation of the results as 
well as in the validity of the statistical analysis.  
In the present study, we confirmed the gonadotoxic effect of 
Cyclophosphamide. The number of primordial and primary follicles was reduced when 
Cy is administered compared to the control, whatever the mice were co-treated with 
GnRHa or not. While the drug- and dose-dependent manner whereby cancer 
treatments affect the ovarian reserve is generally accepted (Meirow, 2001a, 2001b; 
Arnon et al., 2001), it must be emphasized that when we pooled our experiments, a 
significant depletion of the follicles was confirmed  (-30,7%, p=0.002), but still did not 
reach half of the ovarian reserve as predicted for the same Cy concentration using in 
other studies (Meirow, 1999; Meirow et al., 2004). The difference may be related to the 
follicular count methodology but also to technical issues, as for example, the Cy dilution 
and ip injection. Known to be an extremely perishable and delicate compound 
(photosensitive), Cy may also crystalize in the peritoneum at the time of the injection, 
so it does not disseminate properly into the bloodstream, resulting in a weak effect. 
Nevertheless, these preliminary results seem to support the hypothesis that alkylating 
agents harm the growing follicles, inducing a subsequent recruitment of the initial 
follicular pool into the growing process (Blumenfeld et al., 2008). This mechanism of 
action has been reported as the “burn out” action of chemotherapeutical agents.  
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In order to avoid the damage created by chemotherapy, some authors have 
proposed a non-invasive procedure able to suppress the hypothalamic-pituitary-ovarian 
axis, thus interrupting the follicular growing process and consequently protecting the 
ovarian reserve, and so the fertility. This potential strategy is the concomitant 
administration of GnRHa along with chemotherapy. The effect of GnRHa in parallel to 
chemotherapy has been examined both in humans and animal models (Ataya et al., 
1985; Ataya et al., 1995; Blumenfeld et al., 2008; Del Mastro et al., 2011; Meirow et al., 
2004; Tan et al., 2010; Whitehead et al., 2011). In humans, Blumenfeld et al., have 
reported lower rates of POF in women co-treated with GnRHa (11.1%) compared to the 
chemotherapy-only group (55%) in an observational study (Blumenfeld et al., 2008).  
Among GnRHa co-treated women, 22% get pregnant after chemotherapy, compared 
with 14% of those without GnRH agonist therapy (Clowse et al., 2009). Most of these 
studies were observational or/and included important bias maintaining the debate 
around the real efficiency of this treatment and its mechanism of action. Despite some 
promising effects of GnRH analogues, there are indeed many variables that are not 
uniform between trials, thus becoming difficult to evaluate, to compare them and 
therefore to make trustful conclusions: randomised/non-randomised clinical trials, 
sample size, follow-up time, GnRHa treatment, chemotherapy regimen, less sensitive 
markers (pregnancy rate, resumption of menstruation, levels of serum sex steroids and 
gonadotropins), etc. Few recent randomized studies still show contradictory results. 
Among them, some did not show difference in the premature ovarian failure rate  after 
chemotherapy with or without GnRha co-treatment (Behringer et al., 2010; Demeestere 
et al.,  2012), resulting in the persistence of the controversies after more than 20 years 
of investigations.  
We are aware of the incomplete understanding of all the effects and 
mechanisms underlying this kind of co-treatments, or even the existence of a true 
positive effect. While the profound inhibition of gonadotropins secretion was reported 
as the main mechanism of protection, no clear evidence supporting this hypothesis is 
available. Moreover, once there is no expression of FSH receptors on primordial 
follicles, this mechanism cannot be explained by its direct effect on the ovarian follicles 
(Oktay et al., 1997). Another proposed mechanism by which GnRHa may provide 
ovarian protection is through a decrease in ovarian blood flow, consequently causing a 
reduction in the amount of chemotherapy reaching the ovary (Reinsch et al., 1994). 
However, studies on the effect of GnRHa on blood flow are still few and contradictory 
(Kitajima et al., 2006).  
Hence, it is still much more critical to consider that there are still many 
questions to be addressed and answered, so more animal model studies are urgently 
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needed. However, several studies have already contributed to increase controversy 
around the GnRHa putative ovarian protection during chemotherapy. In 1995, a non-
human primate experiment demonstrated that GnRHa significantly decrease the 
follicular depletion associated with gonadotoxic cyclophosphamide treatment (Ataya et 
al., 1995). Bokser et al., using female rats suggested that treatment with GnRHa 
microcapsules before and during chemotherapy prevented the ovarian injury caused by 
Cy (Bokser et al., 1990). Meirow and his colleagues demonstrated the same 
conclusions in the mouse, using the GnRH antagonist cetrorelix (Meirow et al., 2004). 
On the other hand, numerous other authors, using rat and mouse model, have 
advocated that this protection was not present or not statistically significant (Danforth et 
al., 2005; Gosden et al., 1997; Montz et al., 1991). 
The number of follicles, especially primordial follicles, is the more accurate 
estimation of the ovarian reserve (Oktem et al., 2007). Thus, presently, quantitative 
measurement of ovarian follicles in different stages appears as the best way to validate 
or not the protective effect of a GnRH analogue, besides some incongruities and 
difficulties sometimes associated with the counting (Tilly, 2003).  
Our results seem to indicate a non-preventive effect of GnRHa (both agonist 
and antagonist) along a follicle disruption produced by a Cy treatment. Furthermore, 
the mice treated with GnRHa alone showed also a decrease on the initial follicles pool: 
-17% and -23% in the GnRH antagonist and in the agonist groups respectively, when 
compared with the control. Despite they did not reach significance, these results may 
suggest a possible negative effect of the treatment on the ovary. Furthermore, the 
proportion of growing follicles was similar whatever the treatment. Surprisingly, these 
results suggest that GnRHa treatment might not totally inhibit the recruitment of the 
growing follicular pool. The presence of growing follicles was not mentioned in the 
previous published studies using similar protocol and other hormonal tests confirming 
that ovarian suppression was until now poorly investigated. The ovarian function of the 
treated mice have thus to be further evaluated using analysis of  ovarian reserve 
markers, such as serum levels of follicle-stimulating hormone (FSH), estradiol, etc. 
(Luchtman Singh et al., 2007) in the blood samples previously collected. In addition, 
histological analysis will further indicate the proliferation capacity and the viability of 
these follicles. Therefore, we planned to evaluate the proliferation and the apoptosis 
associated to the granulosa cells, respectively testing the activity/presence of the 
proteins Ki-67 and caspase-3.  
However, we already tested the capacity of these secondary follicles, isolated 
after treatment, to develop in vitro until pre-ovulatory stage. This individual 2-D culture 
system was used in our laboratory as a model to follow the development potential of 
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each secondary follicle and to test subsequent oocyte maturation competence 
(Demeestere et al., 2002; Demeestere et al., 2004). In order to compare each 
treatment effect, we tried to isolate a similar number of follicles; however, a non-
significant difference in the survival rate was observed in the different groups. 
Furthermore, oocytes grown in vitro acquired similar maturation competence and 
follicles are able to secrete progesterone in response to hCG/EGF. Besides the non-
significant differences (maybe due to the small size of the sample), it seems however 
that both GnRHa alone reduced subsequent progesterone production in response to 
hCG. Altogether, these results suggested that the folliculogenesis was not altered 
anymore by the chemotherapy treatment after one week. On the other hand, they also 
showed that analogues treatment did not affect the development potential of the 
follicles, at least until secondary stage. These results confirmed previous studies on 
FSHβ knockout model showing that the recruitment of the initial follicular population 
was not completely inhibited in the absence of FSH (Demeestere et al., 2002). 
However, the follicular growth is delayed and in adults, Fshβ-/- individuals contained 
fewer secondary follicles than wild-type individuals and no large antral follicles. These 
observations may be more consistent with what is observed in human during GnRH 
analogues treatment. Further investigations are thus necessary to demonstrate the 
efficiency of the treatment and the validity of the mice model for such studies. 
As mentioned above, another question addressed in our study was the fertility 
of the treated females. If the Cy-treated females show a decrease in the ovarian 
reserve at histological level, probably due to the constant recruitment and demise of 
the growing follicles, one can predict that the reproductive capacity of these females 
would be severely affected. So, we hypothesized that the number of mice per litter 
would start to decrease quicker in these females than in the control. However, our 
treated-mice did not show any decline of their fertility even after seven litters. As such, 
the experiment should continue, in order to verify if the expected alteration of the 
fertility will arise. 
In conclusion, despite this study is still ongoing, the results obtained addressed many 
question regarding this model and further emphasize the necessity to validate it before 
drawing conclusions and extrapolating them in human. At this point, our animal study 
did not show any protective effect of either GnRH agonist or antagonist on 
chemotherapy-induced damage in the ovaries. However, the efficiency of this treatment 
protocol to induce profound inhibition of gonadotropins secretion as observed in 
human, and therefore, of the follicular growth process must be further confirmed. 
Moreover, the doses of the chemotherapy should be adapted in order to increase the 
ovarian damage without inducing immediate irreversible sterility. 
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